Harold Keer joined Astex Pharmaceuticals, Inc. in February 2013, and was appointed Chief Medical Officer in November 2020. He possesses more than 20 years of drug development experience in industry and academia. From 2008 to 2013, Dr. Keer served as Vice President, Clinical Development at Five Prime Therapeutics where he led clinical development for programs in oncology and immunology. From 2002 to 2008 he was at Exelixis where he held multiple roles with increasing responsibility including Vice President, Clinical Development. At Exelixis he was responsible for oversight of multiple clinical development clinical programs including for Cometriq®, now approved for thyroid cancer. Dr. Keer received his MD and PhD degrees from Northwestern University Medical School, completed training in Internal Medicine at Harvard-affiliate, Beth Israel Hospital, and completed sub-specialty training in Medical Oncology at Stanford University School of Medicine where he was awarded a Clinical Associate Physician grant to perform clinical and translational research. He has published many scientific papers and abstracts, including in the New England Journal of Medicine. Dr. Keer is Adjunct Clinical Faculty at Stanford.